Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Company Overview

Daiichi Sankyo Co., Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells. Its oncology portfolio includes trastuzumab deruxtecan, marketed as Enhertu in collaboration with AstraZeneca, as well as other targeted cancer therapies and candidates under development. The company also has medicines addressing cardiovascular conditions and other serious diseases.

The company was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo. Its corporate roots extend to pharmaceutical businesses established in Japan during the late 19th and early 20th centuries. Daiichi Sankyo is headquartered in Tokyo and serves patients and healthcare providers across Japan, North America, Europe and other international markets.

Key Stats

• Today's Range: $16.35 to $16.62
• 50-Day Range: $16.30 to $19.00
• 52-Week Range: $14.98 to $25.69
• Volume: 372,772 shs
• Average Volume: 125,405 shs
• Market Capitalization: $30.85 billion
• P/E Ratio: 19.26
• Dividend Yield: 2.05%
• Price Target: N/A
• Consensus Rating: Reduce

Daiichi Sankyo Stock Analysis - MarketRank™

Daiichi Sankyo scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Daiichi Sankyo has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Daiichi Sankyo has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.13%

Earnings Growth

Earnings for Daiichi Sankyo are expected to grow by 16.13% in the coming year, from $0.93 to $1.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Daiichi Sankyo is 19.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.11.

Price to Earnings Ratio vs. Sector

The P/E ratio of Daiichi Sankyo is 19.26, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.18.

Price to Earnings Growth Ratio

Daiichi Sankyo has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Daiichi Sankyo has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Daiichi Sankyo has been sold short.

Short Interest Ratio / Days to Cover

Daiichi Sankyo has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daiichi Sankyo has recently decreased by 81.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Daiichi Sankyo pays a meaningful dividend of 1.93%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Daiichi Sankyo does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Daiichi Sankyo is 39.53%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Daiichi Sankyo will have a dividend payout ratio of 31.48% next year. This indicates that Daiichi Sankyo will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Daiichi Sankyo has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Daiichi Sankyo this week, compared to 1 article on an average week.

Search Interest

2 people have searched for DSNKY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.

Percentage Held by Institutions

Daiichi Sankyo has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 10/29/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DSNKY
• Previous Symbol: OTCMKTS:DSNKY
• CIK: N/A
• Web: www.daiichisankyo.com
• Phone: (136) 225-1111
• Fax: N/A
• Employees: 20,171
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): $0.86
• Trailing P/E Ratio: 19.26
• Forward P/E Ratio: 17.81
• P/E Growth: 1.9
• Net Income: $1.72 billion
• Net Margins: 10.92%
• Pretax Margin: 12.41%
• Return on Equity: 14.35%
• Return on Assets: 6.10%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.92
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $14.10 billion
• Price / Sales: 2.19
• Cash Flow: $1.10 per share
• Price / Cash Flow: 15.10
• Book Value: $5.80 per share
• Price / Book: 2.86

Miscellaneous

• Outstanding Shares: 1,862,890,000
• Free Float: N/A
• Market Cap: $30.85 billion
• Optionable: Not Optionable
• Beta: -0.11